An immuno-oncology drug, Pembrolizumab, recently received regulatory approval by the South African Health Products Regulatory Authority.Ā Dr Ronwyn van Eeden tells us more about the new drug.
Pembrolizumab has been registered in SA for two types of cancers. The first is a type of lung cancer, called non-small cell lung cancer. Itās registered for patients who have failed or Ā Ā progressed after initial treatment, such as chemotherapy. Usually the drug works better if the expression of PD-L1 (programmed cell death ligand-1) on the cancer is more than 51% as shown in clinical trials. The amount of PD-L1 on the…